Aptamers Market Report 2026

The aptamers market size has grown exponentially in recent years. It will grow from $3.25 billion in 2025 to $4.05 billion in 2026 at a compound annual growth rate (CAGR) of 24.6%. The growth in the historic period can be attributed to growing demand for precision therapeutics, advancement in molecular biology techniques, increasing research funding for aptamer technologies, rising prevalence of chronic diseases, expansion of biotechnology research infrastructure.

The aptamers market size is expected to see exponential growth in the next few years. It will grow to $9.84 billion in 2030 at a compound annual growth rate (CAGR) of 24.8%. The growth in the forecast period can be attributed to increasing adoption of aptamer-based diagnostics, technological integration with AI and biosensing platforms, growth in personalized medicine, rising collaborations between pharma and biotech companies, expansion in emerging markets for research and healthcare. Major trends in the forecast period include advanced targeted drug development, high-throughput screening techniques, customizable aptamer design, integration with biosensors and diagnostics, therapeutic and diagnostic market expansion.

The rising prevalence of chronic respiratory diseases is expected to drive the growth of the aptamers market in the coming years. Chronic respiratory disease occurs when the airways become narrowed and inflamed and may produce excess mucus, making breathing difficult and leading to symptoms such as coughing, shortness of breath, and wheezing during exhalation. Aptamers support the detection of respiratory syncytial virus (RSV), enable early disease identification, and assist in treatment applications. For example, in June 2024, according to the Australian Institute of Health and Welfare, chronic obstructive pulmonary disease (COPD) accounted for 3.6% of the total disease burden and 50% of the disease burden related to respiratory conditions in 2023. Therefore, the increasing prevalence of chronic respiratory diseases is contributing to the growth of the aptamers market.

Major companies operating in the aptamers market are introducing innovative reagents such as Optimer-Fc to address challenges in the immunohistochemistry (IHC) market. Optimer-Fc is a novel reagent designed to automate immunohistochemistry workflows. For example, in March 2023, Aptamer Group PLC, a UK-based biotechnology company, launched Optimer-Fc for use in automated IHC applications, targeting existing limitations within the IHC market. The company collaborates with leading IHC firms, validates the performance of Optimer-Fc, and engages in trial discussions with major pharmaceutical companies. Optimer-Fc, which serves as an alternative to antibodies, integrates Optimer binders into established workflows and offers improved accuracy and selectivity for detecting disease biomarkers in IHC applications. This innovation is particularly significant in light of patent expirations for IHC antibodies, as it provides a new, patentable solution.

In June 2025, Illumina, a US-based genomics and sequencing company, acquired SomaLogic for US$ 350 million in cash, along with up to US$ 75 million in performance-based milestone payments. Through this acquisition, Illumina seeks to advance its multi-omics strategy by incorporating SomaLogic’s aptamer-based proteomics platform, SomaScan, and expanding its capabilities in high-throughput protein biomarker discovery. SomaLogic is a US-based company that offers aptamer-based proteomic solutions using SOMAmers to measure thousands of proteins from biological samples.

Major companies operating in the aptamers market are Aptamer Group Limited, SomaLogic Inc., Aptamer Sciences Inc., Aptagen LLC, NeoVentures Biotechnology Inc., Aptus Biotech, Base Pair Biotechnologies Inc., AMS Biotechnology Ltd., Vivonics Inc., TriLink Biotechnologies LLC, Noxxon Pharma SE, AM Biotechnologies LLC, Raptamer Discovery Group, Kaneka Corporation, Novaptech Inc., Maravai Lifesciences Inc., Bio-Techne Corporation, Creative Biolabs Inc., IBA Lifesciences GmbH, Aptabharat Innovations Pvt. Ltd., Profacgen Biotech Inc., Medi GmbH & Co. KG, Pure Biologics Sp. z o.o., Oak BioSciences Inc., Ophthotech Corporation, Novartis AG, NeoNeuro SAS, CAGE Bio Inc., TAGCyx Biotechnologies Inc., AstraZeneca PLC, GlyTech Inc., GC Biopharma Corp., Achiko AG, Agilent Technologies Inc., IVERIC bio Inc.

North America was the largest region in the aptamers market in 2025. The regions covered in the aptamers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the aptamers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the aptamers market by increasing the cost of importing raw oligonucleotides and laboratory reagents, disrupting supply chains, and slowing production for research and therapeutic applications. Regions like North America, Europe, and Asia-Pacific face higher costs in DNA, RNA, and XNA aptamer production, affecting pharmaceutical and biotechnology companies the most. However, tariffs have also encouraged localized manufacturing and investments in domestic production capacities, fostering innovation and reducing dependency on imports over time.

The aptamers market research report is one of a series of new reports that provides aptamers market statistics, including aptamers industry global market size, regional shares, competitors with a aptamers market share, detailed aptamers market segments, market trends and opportunities, and any further data you may need to thrive in the aptamers industry. This aptamers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Aptamers are short, synthetic, single-stranded oligonucleotides that fold into well-defined structures and bind to target antigens such as proteins, molecules, peptides, cells, and tissues. They are used for the molecular recognition of specific targets.

The main types of aptamers include DNA aptamers, XNA aptamers, and RNA aptamers. DNA aptamers are deoxyribonucleic acid oligonucleotides capable of binding to specific targets with high affinity and specificity, including peptides, small molecules, cells, proteins, and tissues. They are used in the development of drug delivery systems. The technologies involved include SELEX, X-aptamer, and MARAS techniques, which are applied in therapeutic development, research and development, diagnostics, and other applications. The end users include pharmaceutical and biotechnology companies, academic and government research institutes, cathode-ray oscilloscopes, and others.

The aptamers market includes revenues earned by entities by providing RNA profiling and detecting cells, viruses, sugars, and antibodies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.